POLICY BRIEF

Tackling Antimicrobial Resistance
in Line with Global Health Goals

Antimicrobial resistance (AMR) threatens to undermine decades of progress in medicine and public health. AMR occurs when microorganisms such as bacteria, viruses, fungi, and parasites evolve to resist the effects of antimicrobial drugs, rendering treatments ineffective. The World Health Organization (WHO) identifies AMR as a top global health threat and emphasizes its relevance to Sustainable Development Goal (SDG) 3, which aims to “ensure healthy lives and promote well-being for all at all ages,” and SDG 12, which calls for responsible consumption and production patterns. Addressing AMR requires a One Health approach, integrating efforts across human, animal, and environmental health. This Fast-Track Health policy brief explores best practices through five case studies, discusses challenges and opportunities, and provides actionable recommendations for municipal, national, and regional health authorities.

National AMR Strategy in the United Kingdom: The UK’s Five-Year National Action Plan on Antimicrobial Resistance (2019–2024) focuses on reducing inappropriate antimicrobial use by 15% and increasing public awareness. The strategy includes antimicrobial stewardship programs in hospitals, prescriber training, and a national surveillance system for resistance patterns. Early results show a 10% reduction in human antibiotic use within three years. The UK’s model highlights the importance of national strategies and coordinated efforts to combat AMR. (BMJ Global Health, 2023)

Farm-Level Stewardship in Denmark: Denmark has been a global leader in reducing antimicrobial use in agriculture. Its DANMAP program monitors antimicrobial use and resistance trends in both human and veterinary sectors. Policies banning non-therapeutic antibiotic use in livestock have significantly reduced resistance levels in zoonotic pathogens. The Danish experience demonstrates the value of integrating human and animal health in AMR strategies. (The Lancet Infectious Diseases, 2023)

Antibiotic Smart Use Program in Thailand: Thailand’s Antibiotic Smart Use (ASU) program aims to reduce inappropriate antibiotic prescriptions in primary care and community pharmacies. The program provides training for healthcare providers, public education campaigns, and evidence-based prescribing guidelines. Within five years, antibiotic prescriptions for upper respiratory tract infections declined by 30%. Thailand’s initiative highlights the role of behavior change and education in addressing AMR. (WHO SEARO, 2022)

Surveillance and Policy Integration in South Africa: South Africa’s National Institute for Communicable Diseases (NICD) leads an AMR surveillance program that monitors resistance trends and informs policy-making. The program integrates data from hospitals, laboratories, and veterinary sources to provide a comprehensive view of AMR. During the COVID-19 pandemic, the surveillance system identified trends in secondary bacterial infections and antibiotic overuse, enabling targeted interventions. South Africa’s model underscores the importance of integrated surveillance for effective AMR management. (The Lancet Regional Health – Africa, 2023)

Environmental AMR Monitoring in India: India’s National Action Plan on AMR includes provisions for monitoring antimicrobial residues in the environment, particularly in wastewater from pharmaceutical manufacturing. Pilot programs have identified hotspots of resistance genes in water bodies near industrial sites, leading to stricter regulatory enforcement. India’s efforts demonstrate the critical role of environmental monitoring in a One Health approach to AMR. (Nature Microbiology, 2023)

Efforts to tackle AMR face numerous challenges. Inadequate surveillance systems in many low- and middle-income countries (LMICs) limit the ability to detect resistance patterns and implement targeted interventions. Overuse and misuse of antimicrobials in human medicine and agriculture remain widespread, often due to weak regulatory frameworks and insufficient awareness. The lack of financial incentives for pharmaceutical companies to develop new antibiotics exacerbates the problem, leading to a stagnation in the development pipeline. Global inequities in access to quality antimicrobials contribute to resistance, as counterfeit or substandard drugs remain prevalent in many regions. Environmental contamination from pharmaceutical manufacturing and agricultural runoff further accelerates the spread of resistance genes. Additionally, the complexity of coordinating multisectoral responses across human, animal, and environmental health presents logistical and policy challenges.

Despite these challenges, there are significant opportunities to combat AMR. Strengthening surveillance systems, as demonstrated in South Africa, can improve the detection of resistance trends and inform evidence-based policies. National action plans, like those in the UK and Thailand, provide frameworks for antimicrobial stewardship, public education, and regulatory enforcement. The One Health approach, integrating human, animal, and environmental health, offers a holistic strategy for addressing AMR, as seen in Denmark and India. Advances in digital health tools and genomics enable real-time monitoring of resistance genes, providing actionable insights for policymakers. Global initiatives such as the WHO Global AMR Surveillance System (GLASS) and the Global Antibiotic Research and Development Partnership (GARDP) create opportunities for international collaboration and resource-sharing. Increased advocacy for sustainable antibiotic development, coupled with financial incentives for pharmaceutical innovation, can revitalize the antibiotic pipeline and address emerging resistance threats.